In the 20 years since human embryonic stem cells, and subsequently induced pluripotent stem cells, were first described, it has become apparent that during long-term culture these cells (collectively referred to as ‘pluripotent stem cells’ (PSCs)) can acquire genetic changes, which commonly include gains or losses of particular chromosomal regions, or mutations in certain cancer-associated genes, especially TP53. Such changes raise concerns for the safety of PSC-derived cellular therapies for regenerative medicine. Although acquired genetic changes may not be present in a cell line at the start of a research programme, the low sensitivity of current detection methods means that mutations may be difficult to detect if they arise but are present in only a small proportion of the cells. In this Review, we discuss the types of mutations acquired by human PSCs and the mechanisms that lead to their accumulation. Recent work suggests that the underlying mutation rate in PSCs is low, although they also seem to be particularly susceptible to genomic damage. This apparent contradiction can be reconciled by the observations that, in contrast to somatic cells, PSCs are programmed to die in response to genomic damage, which may reflect the requirements of early embryogenesis. Thus, the common genetic variants that are observed are probably rare events that give the cells with a selective growth advantage.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A. & Bongso, A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399–404 (2000).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).
da Cruz, L. et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat. Biotechnol. 36, 328–337 (2018).
Schwartz, S. D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379, 713–720 (2012).
Song, W. K. et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep. 4, 860–872 (2015).
Mandai, M., Kurimoto, Y. & Takahashi, M. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 377, 792–793 (2017).
Barker, R. A., Parmar, M., Studer, L. & Takahashi, J. Human trials of stem cell-derived dopamine neurons for Parkinson’s disease: dawn of a new era. Cell Stem Cell 21, 569–573 (2017).
Bar, S. & Benvenisty, N. Epigenetic aberrations in human pluripotent stem cells. EMBO J. https://doi.org/10.15252/embj.2018101033 (2019).
Yasuda, S. et al. Tumorigenicity-associated characteristics of human iPS cell lines. PLoS ONE 13, e0205022 (2018).
Sato, Y. et al. Tumorigenicity assessment of cell therapy products: the need for global consensus and points to consider. Cytotherapy 21, 1095–1111 (2019).
Andrews, P. W. From teratocarcinomas to embryonic stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 405–417 (2002).
Garber, K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat. Biotechnol. 33, 890–891 (2015).
Hussein, S. M. et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58–62 (2011).
Rouhani, F. J. et al. Mutational history of a human cell lineage from somatic to induced pluripotent stem cells. PLoS Genet. 12, e1005932 (2016).
Steichen, C., Hannoun, Z., Luce, E., Hauet, T. & Dubart-Kupperschmitt, A. Genomic integrity of human induced pluripotent stem cells: reprogramming, differentiation and applications. World J. Stem Cell 11, 729–747 (2019).
Amps, K. et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat. Biotechnol. 29, 1132–1144 (2011). Amps et al. report a study of a large panel of cells lines by an international consortium, using karyotype and SNP array analyses to survey the range of genetic variants commonly recurring in human PSCs.
Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229–233 (2017). The work by Merkle et al. provides the first demonstration of point mutations that occur recurrently in a single gene in human PSCs, resulting in variants of a tumour suppressor that provide a growth advantage by reducing sensitivity to apoptosis.
Olariu, V. et al. Modeling the evolution of culture-adapted human embryonic stem cells. Stem Cell Res. 4, 50–56 (2010).
Thompson, O. et al. Low rates of mutation in clinical grade human pluripotent stem cells under different culture conditions. Nat. Commun. 11, 1528 (2020). Using a clonogenic strategy, Thompson et al. report the low mutation rate in human PSCs and show that this rate is reduced by growth under low-oxygen conditions.
Draper, J. S. et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotechnol. 22, 53–54 (2004).
Taapken, S. M. et al. Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat. Biotechnol. 29, 313–314 (2011).
Baker, D. et al. Detecting genetic mosaicism in cultures of human pluripotent stem cells. Stem Cell Rep. 7, 998–1012 (2016). Baker et al. provide a comprehensive comparison of the sensitivity of commonly used methods for detection of genetic changes in PSCs, providing the basis for interpreting genetic tests used for assessment of PSC cultures.
Torres, E. M., Williams, B. R. & Amon, A. Aneuploidy: cells losing their balance. Genetics 179, 737–746 (2008).
Assou, S. et al. Recurrent genetic abnormalities in human pluripotent stem cells: definition and routine detection in culture supernatant by targeted droplet digital PCR. Stem Cell Rep. 14, 1–8 (2020).
Baker, D. E. et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat. Biotechnol. 25, 207–215 (2007).
Nguyen, H. T., Geens, M. & Spits, C. Genetic and epigenetic instability in human pluripotent stem cells. Hum. Reprod. Update 19, 187–205 (2013).
Lefort, N. et al. Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. Nat. Biotechnol. 26, 1364–1366 (2008).
Spits, C. et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat. Biotechnol. 26, 1361–1363 (2008).
Enver, T. et al. Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem cells. Hum. Mol. Genet. 14, 3129–3140 (2005).
Ben-David, U. et al. Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. Nat. Commun. 5, 4825 (2014). Ben-David et al. provide a detailed analysis of how gains of chromosome 12, one of the common chromosomal variants seen in human PSCs and in germ cell tumours, affect the transcriptome and the growth patterns of human PSCs.
Avior, Y., Eggan, K. & Benvenisty, N. Cancer-related mutations identified in primed and naive human pluripotent stem cells. Cell Stem Cell 25, 456–461 (2019).
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W. & Chang, E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747–749 (1990).
Nichols, J. & Smith, A. Naive and primed pluripotent states. Cell Stem Cell 4, 487–492 (2009).
Mostofi, F. K. & Price, E. B. Tumors of the Male Genital System, Atlas of Tumor Pathology, Second Series. (Armed Forces Institute of Pathology, 1973).
Damjanov, I. & Solter, D. Experimental teratoma. Curr. Top. Pathol. 59, 69–130 (1974).
Damjanov, I. & Andrews, P. W. The terminology of teratocarcinomas and teratomas. Nat. Biotechnol. 25, 1212 (2007).
Damjanov, I. & Andrews, P. W. Teratomas produced from human pluripotent stem cells xenografted into immunodeficient mice - a histopathology atlas. Int. J. Dev. Biol. 60, 337–419 (2016).
Einhorn, L. H. & Donohue, J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87, 293–298 (1977).
Oosterhuis, J. W., Andrews, P. W., Knowles, B. B. & Damjanov, I. Effects of cis-platinum on embryonal carcinoma cell lines in vitro. Int. J. Cancer 34, 133–139 (1984).
Einhorn, L. H., Nagy, C., Furnas, B. & Williams, S. D. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J. Clin. Pharmacol. 21, 64S–69S (1981).
Williams, S. D. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435–1440 (1987).
Andrews, P. W. et al. Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin. Biochem. Soc. Trans. 33, 1526–1530 (2005).
Allison, T. F. et al. Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells. Nat. Commun. 9, 1925 (2018).
Cunningham, J. J., Ulbright, T. M., Pera, M. F. & Looijenga, L. H. Lessons from human teratomas to guide development of safe stem cell therapies. Nat. Biotechnol. 30, 849–857 (2012).
Plantaz, D. et al. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol. 150, 81–89 (1997).
Avery, S. et al. BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures. Stem Cell Rep. 1, 379–386 (2013). Avery et al. report the identification of BCL2L1 as the driver gene on chromosome band 20q11.21, which is commonly amplified in PSCs.
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
Hainaut, P. & Hollstein, M. in Advances in Cancer Research Vol. 77 (eds Vande Woude, G. F. & Klein, G.) 81–137 (Academic Press, 1999).
Andrews, P. W. et al. Assessing the safety of human pluripotent stem cells and their derivatives for clinical applications. Stem Cell Rep. 9, 1–4 (2017).
Technologies, S. Challenges in Ensuring hPSC Quality. Stemcell.com, https://www.stemcell.com/nature-research-roundtable-hPSC-quality (2018).
Ministry of Health, Labour and Welfare. English translation of Annex of Notification 0613-3. http://www.nihs.go.jp/cbtp/sispsc/pdf/Eg.ver.Annex_0613-3_2016.pdf (2016).
Catalina, P. et al. Human ESCs predisposition to karyotypic instability: is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Mol. Cancer 7, 76 (2008).
Imreh, M. P. et al. In vitro culture conditions favoring selection of chromosomal abnormalities in human ES cells. J. Cell Biochem. 99, 508–516 (2006).
Andrews, P. W., Bronson, D. L., Benham, F., Strickland, S. & Knowles, B. B. A comparative study of eight cell lines derived from human testicular teratocarcinoma. Int. J. Cancer 26, 269–280 (1980).
Andrews, P. W., Goodfellow, P. N., Shevinsky, L. H., Bronson, D. L. & Knowles, B. B. Cell-surface antigens of a clonal human embryonal carcinoma cell line: morphological and antigenic differentiation in culture. Int. J. Cancer 29, 523–531 (1982).
Fazeli, A. et al. Altered patterns of differentiation in karyotypically abnormal human embryonic stem cells. Int. J. Dev. Biol. 55, 175–180 (2011).
Werbowetski-Ogilvie, T. E. et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat. Biotechnol. 27, 91–97 (2009). The study by Werbowetski-Ogilvie et al. demonstrates a profound effect of some of the recurrent genetic changes on PSC growth rates and the ability of PSCs to differentiate to specific lineages.
Lee, C. T. et al. Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation. Cell Rep. 10, 616–632 (2015).
Markouli, C. et al. Gain of 20q11.21 in human pluripotent stem cells impairs TGF-β-dependent neuroectodermal commitment. Stem Cell Rep. 13, 163–176 (2019). Markouli et al. show that altered transforming growth factor-β signalling in PSCs harbouring a 20q11.21 copy number variant impairs their neuroectodermal differentiation.
Laurent, L. C. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8, 106–118 (2011).
Ohgushi, M. et al. Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell 7, 225–239 (2010).
Barbaric, I. et al. Time-lapse analysis of human embryonic stem cells reveals multiple bottlenecks restricting colony formation and their relief upon culture adaptation. Stem Cell Rep. 3, 142–155 (2014).
Liu, J. C. et al. High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell 13, 483–491 (2013).
Dumitru, R. et al. Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. Mol. Cell 46, 573–583 (2012).
Price, C. J. et al. Genetically variant human pluripotent stem cells selectively eliminate wild-type counterparts through YAP-mediated cell competition. bioRxiv https://doi.org/10.1101/854430 (2019).
Bowling, S., Lawlor, K. & Rodríguez, T. A. Cell competition: the winners and losers of fitness selection. Development https://doi.org/10.1242/dev.167486 (2019).
Haupt, S., Mejía-Hernández, J. O., Vijayakumaran, R., Keam, S. P. & Haupt, Y. The long and the short of it: the MDM4 tail so far. J. Mol. Cell Biol. 11, 231–244 (2019).
Blum, B., Bar-Nur, O., Golan-Lev, T. & Benvenisty, N. The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat. Biotechnol. 27, 281–287 (2009).
Mesri, M., Wall, N. R., Li, J., Kim, R. W. & Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108, 981–990 (2001).
Ma, X. et al. High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro. J. Biotechnol. 123, 367–378 (2006).
Yang, D., Welm, A. & Bishop, J. M. Cell division and cell survival in the absence of survivin. Proc. Natl Acad. Sci. USA 101, 15100–15105 (2004).
Atkin, N. B. & Baker, M. C. Specific chromosome change, i(12p), in testicular tumours? Lancet 2, 1349 (1982).
Rodriguez, S. et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 22, 1880–1891 (2003).
Korkola, J. E. et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 66, 820–827 (2006).
Chambers, I. et al. Nanog safeguards pluripotency and mediates germline development. Nature 450, 1230–1234 (2007).
Darr, H., Mayshar, Y. & Benvenisty, N. Overexpression of NANOG in human ES cells enables feeder-free growth while inducing primitive ectoderm features. Development 133, 1193–1201 (2006).
Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20, 175–193 (2019).
Madden, D. T., Davila-Kruger, D., Melov, S. & Bredesen, D. E. Human embryonic stem cells express elevated levels of multiple pro-apoptotic BCL-2 family members. PLoS ONE 6, e28530 (2011).
Zhang, J. et al. Anti-apoptotic mutations desensitize human pluripotent stem cells to mitotic stress and enable aneuploid cell survival. Stem Cell Rep. 12, 557–571 (2019).
Ardehali, R. et al. Overexpression of BCL2 enhances survival of human embryonic stem cells during stress and obviates the requirement for serum factors. Proc. Natl Acad. Sci. USA 108, 3282–3287 (2011).
Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681–686 (2007).
Milholland, B. et al. Differences between germline and somatic mutation rates in humans and mice. Nat. Commun. 8, 15183 (2017).
Kuijk, E. et al. Mutational impact of culturing human pluripotent and adult stem cells. Nat. Commun. 11, 2493 (2018).
Cervantes, R. B., Stringer, J. R., Shao, C., Tischfield, J. A. & Stambrook, P. J. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc. Natl Acad. Sci. USA 99, 3586–3590 (2002).
Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282–1294.e1220 (2019).
Kucab, J. E. et al. A compendium of mutational signatures of environmental agents. Cell 177, 821–836.e816 (2019).
Viel, A. et al. A Specific mutational signature associated with DNA 8-oxoguanine persistence in MUTYH-defective colorectal cancer. EBioMedicine 20, 39–49 (2017).
Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870 (2005).
Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913 (2005).
Cannan, W. J. & Pederson, D. S. Mechanisms and consequences of double-strand DNA break formation in chromatin. J. Cell Physiol. 231, 3–14 (2016).
Becker, K. A. et al. Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J. Cell Physiol. 209, 883–893 (2006).
Becker, K. A. et al. Cyclin D2 and the CDK substrate p220NPAT are required for self-renewal of human embryonic stem cells. J. Cell Physiol. 222, 456–464 (2010).
Filipczyk, A. A., Laslett, A. L., Mummery, C. & Pera, M. F. Differentiation is coupled to changes in the cell cycle regulatory apparatus of human embryonic stem cells. Stem Cell Res. 1, 45–60 (2007).
Halliwell, J. A. et al. Nucleosides rescue replication-mediated genome instability of human pluripotent stem cells. Stem Cell Rep. 14, 1009–1017 (2020). Halliwell et al. show that human PSCs are subject to DNA replication stress that leads to DNA damage, mitotic errors and reduced population growth rates, but that these effects can be greatly reduced by culture in medium supplemented with nucleosides.
Simara, P. et al. DNA double-strand breaks in human induced pluripotent stem cell reprogramming and long-term in vitro culturing. Stem Cell Res. Ther. 8, 73 (2017).
Vallabhaneni, H. et al. High basal levels of γH2AX in human induced pluripotent stem cells are linked to replication-associated DNA damage and repair. Stem Cell 36, 1501–1513 (2018).
Akli, S. & Keyomarsi, K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol. Ther. 2, S38–S47 (2003).
Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145, 435–446 (2011).
Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013).
Frame, F. M., Rogoff, H. A., Pickering, M. T., Cress, W. D. & Kowalik, T. F. E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. Oncogene 25, 3258–3266 (2006).
Pickering, M. T. & Kowalik, T. F. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 25, 746–755 (2006).
Ahuja, A. K. et al. A short G1 phase imposes constitutive replication stress and fork remodelling in mouse embryonic stem cells. Nat. Commun. 7, 10660 (2016).
Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008).
Jones, R. M. et al. Increased replication initiation and conflicts with transcription underlie cyclin E-induced replication stress. Oncogene 32, 3744–3753 (2013).
Cimini, D. et al. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. J. Cell Biol. 153, 517–527 (2001).
Chan, K. L., Palmai-Pallag, T., Ying, S. & Hickson, I. D. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat. Cell Biol. 11, 753–760 (2009).
Naim, V., Wilhelm, T., Debatisse, M. & Rosselli, F. ERCC1 and MUS81-EME1 promote sister chromatid separation by processing late replication intermediates at common fragile sites during mitosis. Nat. Cell Biol. 15, 1008–1015 (2013).
Lukas, C. et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat. Cell Biol. 13, 243–253 (2011).
Lamm, N. et al. Genomic instability in human pluripotent stem cells arises from replicative stress and chromosome condensation defects. Cell Stem Cell 18, 253–261 (2016).
Maynard, S. et al. Human embryonic stem cells have enhanced repair of multiple forms of DNA damage. Stem Cell 26, 2266–2274 (2008).
Momcilović, O. et al. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G2 but not G1 cell cycle arrest in pluripotent human embryonic stem cells. Stem Cell 27, 1822–1835 (2009).
Luo, L. Z. et al. DNA repair in human pluripotent stem cells is distinct from that in non-pluripotent human cells. PLoS ONE 7, e30541 (2012).
Hyka-Nouspikel, N. et al. Deficient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. Stem Cell 30, 1901–1910 (2012).
Adams, B. R., Golding, S. E., Rao, R. R. & Valerie, K. Dynamic dependence on ATR and ATM for double-strand break repair in human embryonic stem cells and neural descendants. PLoS ONE 5, e10001 (2010).
Adams, B. R., Hawkins, A. J., Povirk, L. F. & Valerie, K. ATM-independent, high-fidelity nonhomologous end joining predominates in human embryonic stem cells. Aging 2, 582–596 (2010).
Saretzki, G. et al. Downregulation of multiple stress defense mechanisms during differentiation of human embryonic stem cells. Stem Cell 26, 455–464 (2008).
Desmarais, J. A. et al. Human embryonic stem cells fail to activate CHK1 and commit to apoptosis in response to DNA replication stress. Stem Cell 30, 1385–1393 (2012). The study by Desmarais et al. demonstrates that human PSCs respond differently to DNA replication stress compared with somatic cells, as PSCs fail to activate the CHK1 checkpoint and, instead of arresting and repairing the DNA, PSCs undergo apoptosis.
Desmarais, J. A., Unger, C., Damjanov, I., Meuth, M. & Andrews, P. Apoptosis and failure of checkpoint kinase 1 activation in human induced pluripotent stem cells under replication stress. Stem Cell Res. Ther. 7, 17 (2016).
Hong, Y. & Stambrook, P. J. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc. Natl Acad. Sci. USA 101, 14443–14448 (2004).
van Echten-Arends, J. et al. Chromosomal mosaicism in human preimplantation embryos: a systematic review. Hum. Reprod. Update 17, 620–627 (2011).
Munné, S. et al. First PGT-A using human in vivo blastocysts recovered by uterine lavage: comparison with matched IVF embryo controls. Hum. Reprod. 35, 70–80 (2019).
Starostik, M. R., Sosina, O. A. & McCoy, R. C. Single-cell analysis of human embryos reveals diverse patterns of aneuploidy and mosaicism. bioRxiv https://doi.org/10.1101/2020.01.06.894287 (2020).
Brezina, P. et al. Genetic normalization of differentiating aneuploid human embryos. Nat. Preced. https://doi.org/10.1038/npre.2011.6045.1 (2011).
Kops, G. J., Foltz, D. R. & Cleveland, D. W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl Acad. Sci. USA 101, 8699–8704 (2004).
Bolton, H. et al. Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal developmental potential. Nat. Commun. 7, 11165 (2016).
Hardy, K. Cell death in the mammalian blastocyst. Mol. Hum. Reprod. 3, 919–925 (1997).
Haouzi, D. & Hamamah, S. Pertinence of apoptosis markers for the improvement of in vitro fertilization (IVF). Curr. Med.Chem. 16, 1905–1916 (2009).
Ihry, R. J. et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat. Med. 24, 939–946 (2018).
Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551–565.e558 (2019).
Enache, O. M. et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat. Genet. https://doi.org/10.1038/s41588-020-0623-4 (2020).
Chagtai, T. et al. Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study. J. Clin. Oncol. 34, 3195–3203 (2016).
Walker, B. A. et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116, e56–e65 (2010).
Kilday, J. P. et al. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Societe Francaise d’Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin. Cancer Res. 18, 2001–2011 (2012).
Kraggerud, S. M. et al. Genome profiles of familial/bilateral and sporadic testicular germ cell tumors. Genes Chromosomes Cancer 34, 168–174 (2002).
Bown, N. et al. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children’s Cancer Study Group. Med. Pediatr. Oncol. 36, 14–19 (2001).
Nguyen, H. T. & Duong, H. Q. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol. Lett. 16, 9–18 (2018).
Robertson, G. P., Herbst, R. A., Nagane, M., Huang, H. J. & Cavenee, W. K. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res. 59, 3596–3601 (1999).
Kimmelman, A. C., Ross, D. A. & Liang, B. C. Loss of heterozygosity of chromosome 10p in human gliomas. Genomics 34, 250–254 (1996).
Popat, S. & Houlston, R. S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur. J. Cancer 41, 2060–2070 (2005).
Damjanov, I. & Andrews, P. W. The terminology of teratocarcinomas and teratomas. Nat. Biotechnol. 25, 1212 (2007).
Steinemann, D., Göhring, G. & Schlegelberger, B. Genetic instability of modified stem cells - a first step towards malignant transformation? Am. J. Stem Cell 2, 39–51 (2013).
Valli, R. et al. Comparative genomic hybridization on microarray (a-CGH) in constitutional and acquired mosaicism may detect as low as 8% abnormal cells. Mol. Cytogenet. 4, 13 (2011).
Mayshar, Y. et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7, 521–531 (2010).
Weissbein, U., Schachter, M., Egli, D. & Benvenisty, N. Analysis of chromosomal aberrations and recombination by allelic bias in RNA-Seq. Nat. Commun. 7, 12144 (2016).
Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071–1078 (2009).
Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421–429 (2003).
Krokan, H. E. & Bjørås, M. Base excision repair. Cold Spring Harb. Perspect. Biol. 5, a012583 (2013).
Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366–374 (2001).
Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181–211 (2010).
San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77, 229–257 (2008).
This work was funded in part by grants from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 668724 and from the UK Regenerative Medicine Platform, MRC reference MR/R015724/1.
The authors declare no competing interests.
Peer review information
Nature Reviews Molecular Cell Biology thanks Florian Merkle and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
COSMIC Cancer Gene Census database: https://cancer.sanger.ac.uk/census
- Age-related macular degeneration
A common cause of blindness in elderly people due to degeneration of the retinal pigment epithelium underlying the retina.
- Mosaic culture
A culture containing two or more genetically distinct cell types; for example, an original cell type and a genetic variant derived from it.
- Population bottleneck
A situation occurring during successive passaging of cell cultures in which a culture is derived from a very small number of cells from the preceding culture.
- Driver genes
Genes whose altered expression provides the main selective growth advantage associated with a particular genomic variant.
- Clonogenic assays
Assays in which clones of cells are grown out from isolated single cells to assess the properties of the different cells composing a mosaic culture.
An unbalanced genome caused by the presence of an abnormal number of chromosomes or fragments of chromosomes in a cell; it does not include abnormal numbers of chromosomes that are exact multiples of the haploid set of chromosomes (that is, 23 in human cells).
- Interstitial duplications
A type of chromosomal aberration in which a duplicated DNA segment is inserted in the same chromosome.
- Whole-exome sequencing
A method of sequencing all of the protein-coding regions (exome) in the genome.
Embryonic tissue that gives rise to all of the fetal tissues, including the germ line.
- Xenograft tumours
Tumours developing from cells transplanted to a host of a different species; in this Review, typically tumours produced by human cells in an immunodeficient mouse host.
- Primitive endoderm
Cells found in teratomas and closely resembling cells of the extraembryonic endoderm found in the pre-implantation embryo.
A discrete region of the genome that has been duplicated one or more times.
- Hitchhiker genes
Genes present on amplified or deleted chromosome segments with no effect on the growth advantage of the variant cell.
- Cell competition
Cell–cell interaction mechanism leading to elimination of cells that are viable in their homotypic environment in the presence of comparatively fitter cells.
A chromosomal rearrangement in which one whole arm of a chromosome is replaced by a complete copy of the other arm, resulting in a loss of the genes located on the first arm and duplication of the genes located on the other arm.
- Clinical grade
A loose and ill-defined term that identifies cell lines that have been developed and maintained in ways that will satisfy regulatory authorities for clinical application; it is commonly applied to pluripotent stem cell lines that have been derived according to good manufacturing practice.
Genomic changes involving the insertion or deletion of a sequence of one or more nucleotides.
- RB1–E2F checkpoint
Controls the entry into S phase and the initiation of DNA replication during the cell cycle; dependent on the retinoblastoma tumour suppressor protein, RB1, regulating expression of the transcription factor E2F.
- G1/S checkpoint
Also known as the restriction point, safeguards entry into S phase during the cell cycle, where DNA synthesis occurs.
About this article
Cite this article
Halliwell, J., Barbaric, I. & Andrews, P.W. Acquired genetic changes in human pluripotent stem cells: origins and consequences. Nat Rev Mol Cell Biol 21, 715–728 (2020). https://doi.org/10.1038/s41580-020-00292-z
International Journal of Molecular Sciences (2020)